Senator Hatch Criticizes 340B Orphan Drug Exclusion Rule

by Admin | August 2, 2013 12:49 pm

August 2, 2013—Sen. Orrin Hatch (R-Utah) has sent a letter to HRSA[1] Administrator Mary Wakefield saying the agency’s 340B orphan drug exclusion final regulation[2] is “incorrectly interpreting the law” and diminishes incentives for orphan drug development. 

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[3].    Already registered? Click here to login[4]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Endnotes:
  1. letter to HRSA: http://www.snhpa.org/public/documents/pdfs/Letter_Final_Rule_Orphan_Drugs_340B.PDF
  2. 340B orphan drug exclusion final regulation: https://340binformed.org/2013/07/hrsa-publishes-final-340b-orphan-drug-regulation/
  3. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  4. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2013/08/senator-hatch-criticizes-340b-orphan-drug-exclusion-rule/

Copyright ©2026 340binformed.org unless otherwise noted.